Biogen scraps development of therapy for rare brain disease
(Reuters) – Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain…
Multiple sclerosis drug helps Biogen beat Wall St. profit expectations
(Reuters) – Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher…
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
CHICAGO/TOKYO (Reuters) – Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease…
Novartis gene therapy would be cost effective up to $900,000: U.S. group
(Reuters) – An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth…
Biogen’s pricey muscle drug Spinraza too costly for Britain
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service,…